SEE STUDY RESULTS
ANORO was studied in patients with moderate or worse COPD.
ANORO improved lung function more than SPIRIVA† and more than ADVAIR.‡
Individual results may vary. Each product has its own risks and benefits. Please see full Important Safety Information for ANORO ELLIPTA below.
- ANORO is a dual bronchodilator that includes two medicines, a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA).
- SPIRIVA contains one medicine, a bronchodilator (LAMA).
- ADVAIR contains two medicines, an inhaled corticosteroid (ICS) and a bronchodilator (LABA).
†Based on results from 2 of 3 clinical trials comparing ANORO and SPIRIVA HANDIHALER. SPIRIVA is used to treat COPD and reduce COPD flare-ups.
‡Based on results from 2 clinical trials comparing ANORO and ADVAIR DISKUS 250/50. ADVAIR is used to treat COPD and reduce COPD flare-ups.